(BCRX) BioCryst Pharmaceuticals, Inc. BCG Matrix Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(BCRX) BioCryst Pharmaceuticals, Inc. Complete Analysis Pack
See the Bigger Picture
This BioCryst Pharmaceuticals, Inc. BCG Matrix is a company-specific analysis used to see how its products or business units fit into Stars, Cash Cows, Question Marks, and Dogs. The page already shows a real preview of the report content, so you can review the format and depth before buying. Purchase the full version to get the complete ready-to-use analysis instantly.
Stars
ORLADEYO HAE franchise
ORLADEYO is BioCryst Pharmaceuticals, Inc.’s lead marketed product for hereditary angioedema prophylaxis, and it remains the clearest Star in the BCG Matrix: high share, high growth, and still the main commercial engine. As an oral small-molecule therapy, it has broad use potential versus injectable rivals, which supports durable demand. In BioCryst Pharmaceuticals, Inc.’s 2025 results, ORLADEYO continued to drive most product revenue and portfolio value.
ORLADEYO U.S. sales
BioCryst Pharmaceuticals, Inc.'s U.S. ORLADEYO sales are the core growth engine, since the U.S. is the largest market for its only major revenue brand. As a once-daily oral therapy for hereditary angioedema, ORLADEYO keeps gaining uptake in a specialty market where convenience matters, and that supports star status. Continued U.S. demand is the key watch item for 2025 results.
ORLADEYO multi-region approvals
ORLADEYO is approved and commercialized in the U.S., EU, UK, and Japan, giving BioCryst Pharmaceuticals, Inc. a multi-region footprint for hereditary angioedema. That wider reach expands the treatable patient pool beyond one market and lengthens the franchise runway. This is what a Star looks like: strong growth potential plus geographic expansion.
ORLADEYO oral once-daily profile
ORLADEYO's oral once-daily dosing is a clear edge in hereditary angioedema (HAE) prophylaxis, where many rivals are injectable. BioCryst reported ORLADEYO net revenue of 166.8 million in Q1 2025, up 22% year over year, showing the pill form is still helping win share in a growing niche.
- Once-daily oral use improves convenience
- Standout vs injectable HAE prophylaxis
- Q1 2025 revenue: 166.8 million
- Year-over-year growth: 22%
ORLADEYO revenue concentration
In BioCryst Pharmaceuticals, Inc.'s 2025 mix, ORLADEYO still drove almost all product sales, so the company's growth, margin, and cash flow depend heavily on one brand. That kind of concentration is risky, but it also fits a Star in the BCG Matrix because ORLADEYO still has high expansion potential in hereditary angioedema.
- 2025 revenue stayed highly concentrated
- ORLADEYO carried most growth expectations
- High share plus expansion = Star
ORLADEYO Drives BioCryst’s Growth With 22% Q1 Revenue Jump
ORLADEYO is BioCryst Pharmaceuticals, Inc.'s Star: it held 166.8 million of net revenue in Q1 2025, up 22% year over year, and still drove nearly all product sales. Its once-daily oral dosing and approvals in the U.S., EU, UK, and Japan support continued share gains in hereditary angioedema.
| Metric | Value |
|---|---|
| Q1 2025 net revenue | 166.8 million |
| YoY growth | 22% |
| Markets | U.S., EU, UK, Japan |
What is included in the product
Detailed Word Document
BioCryst’s BCG Matrix likely centers on Orladeyo as a Star/Cash Cow, with pipeline assets as Question Marks.
Editable Excel File
Clean, quadrant-based BioCryst Pharmaceuticals BCG Matrix that clarifies portfolio pain points fast.
Reference Sources
Provides a traceable source trail for BioCryst Pharmaceuticals, Inc., boosting credibility and helping decision-makers verify key claims fast.
Cash Cows
Torii Pharmaceutical Japan license
BioCryst Pharmaceuticals, Inc. Japan license with Torii Pharmaceutical is a classic cash cow: a mature local partnership that can bring in royalties with little direct selling spend. In 2025, this kind of asset helps BioCryst offset R&D-heavy cash use while keeping Japan exposure in place. If Torii keeps Orladeyo uptake steady, the stream stays low-risk and margin-rich.
Seqirus UK partnership
Seqirus UK Limited is a named BioCryst collaborator, and this kind of licensing tie-up usually fits a cash cow slot: low capital needs, steady contract cash, and limited expansion spend. BioCryst does not break out Seqirus UK revenue separately in its public filings, so the partnership is best read as a recurring cash-support line rather than a growth engine. That makes it useful for funding core programs without heavy new investment.
Shionogi influenza agreement
Shionogi & Co., Ltd. has been a BioCryst Pharmaceuticals, Inc. partner in Japan for years, and the deal is built on mature regional commercialization rather than early-stage R&D. In a BCG Matrix, that makes it closer to a cash cow: steady, recurring income with low reinvestment needs. It is the kind of long-running agreement that can keep cash flowing even when growth is limited.
Green Cross Korea collaboration
Green Cross Korea is a classic Cash Cow for BioCryst: an established regional partner can keep generating royalty-like cash with limited new selling spend. Mature rights in Korea and nearby markets usually carry high incremental margins, so even modest sales can support steady profit. That fits BioCryst’s 2025-style portfolio logic: low capex, low promotion, recurring cash.
- Established partner, lower commercial spend
- Recurring cash, margin-friendly economics
- Mature rights fit Cash Cow profile
Mundipharma territory rights
Mundipharma International Holdings Limited is one of BioCryst Pharmaceuticals, Inc.'s collaboration assets, and its territory rights fit the Cash Cows bucket because these deals can deliver steady, low-growth royalty income. That cash helps fund R and D and supports liquidity while BioCryst scales Orladeyo, which drove most of the Company's 2025 revenue mix.
- Steady royalty-style cash
- Low capital needs
- Supports R and D funding
- Backs the balance sheet
BioCryst’s Cash Cows: Royalty Deals Funding Growth
BioCryst Pharmaceuticals, Inc.’s Cash Cows are its mature licensing links with Torii Pharmaceutical, Shionogi & Co., Ltd., Green Cross Korea, Mundipharma International Holdings Limited, and Seqirus UK Limited. These deals are low-capex and royalty-like, so they help fund R and D while BioCryst’s 2025 sales were still led by Orladeyo.
| Partner | Cash Cow signal | 2025 |
|---|---|---|
| Torii | Japan royalties | Steady |
| Shionogi | Mature rights | Recurring |
Get Your Copy
BioCryst Pharmaceuticals, Inc. Reference Sources
You’re previewing the exact BioCryst Pharmaceuticals, Inc. BCG Matrix report you’ll receive after purchase. The full document is the same professionally formatted file—no demo pages, no watermarks, no placeholders. Once purchased, it’s ready to download, use, and present immediately.
Dogs
RAPIVAB peramivir injection
RAPIVAB (peramivir injection) is BioCryst Pharmaceuticals, Inc.'s IV antiviral for acute uncomplicated influenza, but influenza antivirals sit in a mature, seasonal market. BioCryst's 2025 filings do not show meaningful RAPIVAB revenue, which points to low share and weak growth, fitting a Dog in the BCG Matrix.
RAPIACTA peramivir brand
RAPIACTA is BioCryst Pharmaceuticals, Inc.’s brand for peramivir, an IV flu drug used in a narrow acute-care setting. The market is highly seasonal, tied to winter flu spikes, so demand is uneven and hard to scale. That limits revenue upside and keeps RAPIACTA in dog territory within the BCG Matrix.
PERAMIFLU peramivir brand
PERAMIFLU (peramivir) sits in BioCryst Pharmaceuticals, Inc.'s mature neuraminidase inhibitor niche, so it fits a Dogs profile with low growth and limited strategic lift. BioCryst has not flagged it as a major 2025–2026 revenue driver, while the company's growth story stays centered on ORLADEYO.
Acute uncomplicated influenza niche
Peramivir is approved for acute uncomplicated influenza, a short-duration, crowded antiviral niche with limited pricing power and little room to expand beyond seasonal demand. That fits the dog quadrant for BioCryst Pharmaceuticals, Inc.: the flu market is dominated by broader, cheaper oral and nasal options, while BioCryst’s HAE franchise and pipeline offer far stronger growth.
- Acute, seasonal use only
- Small share vs HAE growth
- Limited expansion potential
Legacy neuraminidase inhibitor franchise
BioCryst Pharmaceuticals, Inc.’s legacy neuraminidase inhibitor franchise is a Dog in its BCG Matrix: peramivir is an older influenza antiviral with little long-term growth upside, while newer flu assets have been largely eclipsed by better therapies and seasonal demand swings.
The franchise sits far behind ORLADEYO, which drove most of BioCryst Pharmaceuticals, Inc.’s business and reported 2025 net revenue of about $0.0B from this legacy class, versus much stronger growth from newer programs.
- Peramivir is a legacy antiviral asset.
- Influenza drugs face weak growth.
- BioCryst Pharmaceuticals, Inc. should prioritize ORLADEYO.
BioCryst’s Legacy Flu Assets: A Classic Dog
BioCryst Pharmaceuticals, Inc.’s peramivir-based flu assets are Dogs: a mature, seasonal antiviral niche with little growth and weak share. In BioCryst Pharmaceuticals, Inc.’s 2025 filings, this legacy class contributed about $0.0B in net revenue, while ORLADEYO drove the growth story.
| Metric | BioCryst Pharmaceuticals, Inc. |
|---|---|
| 2025 net revenue | about $0.0B |
| Market | seasonal flu antivirals |
| BCG fit | Dog |
Question Marks
BCX9930 Phase II
BCX9930 is BioCryst Pharmaceuticals, Inc.'s oral factor D inhibitor, still in Phase II, so it fits the BCG Matrix "Question Mark" bucket. It targets complement-mediated diseases, but it has 0 commercial share and no product revenue yet. Its value still depends on late-stage clinical data and a clear path to approval.
BCX9250 Phase I
BCX9250 is BioCryst Pharmaceuticals, Inc.’s oral ALK-2 inhibitor in Phase I for fibrodysplasia ossificans progressiva, a rare disease affecting about 1 in 2 million people. That early-stage profile makes it a classic Question Mark in the BCG matrix: high upside, but no proven clinical or commercial fit yet. Its value will depend on Phase I safety and target engagement data.
Galidesivir Phase I
Galidesivir sits in the Question Marks bucket: it is a Phase I RNA dependent-RNA polymerase inhibitor studied against four RNA viruses, Marburg, Yellow Fever, Ebola, and Zika. The broad antiviral idea is attractive, but BioCryst Pharmaceuticals, Inc. has not shown clear market traction or late-stage proof yet, so its commercial payoff remains uncertain.
Complement-mediated diseases pipeline
BioCryst Pharmaceuticals, Inc.'s complement-mediated diseases pipeline is still a Question Mark because it rests mainly on BCX9930, a high-interest oral complement C5 inhibitor in a field with clear growth room. The program can gain share only if it keeps producing strong clinical data and secures more capital to fund larger trials and commercialization.
- BCX9930 is the core asset
- Complement biology has growth room
- Data and capital drive conversion
Fibrodysplasia ossificans progressiva program
BCX9250 targets fibrodysplasia ossificans progressiva, a disease seen in about 1 in 2 million people worldwide, so even small proof-of-concept gains can matter. The unmet need is high because FOP causes progressive bone formation in soft tissue and has no cure. Until BioCryst Pharmaceuticals, Inc. shows clearer efficacy and safety data, the program stays a question mark. Rare-disease pricing can be strong, but the market is tiny.
- Rare disease, high unmet need.
- Small market, strong pricing power.
- Proof of concept still needed.
BioCryst’s Early-Stage Bets: Big Upside, High Execution Risk
BioCryst Pharmaceuticals, Inc.’s Question Marks are BCX9930, BCX9250, and galidesivir: all are early-stage assets with no product revenue and no proven market share yet. BCX9930 is the lead program in Phase II, while BCX9250 and galidesivir are still in Phase I, so each needs strong data to move out of the Question Mark box. The upside is real, but so is the execution risk.
| Asset | Stage | Why it is a Question Mark |
|---|---|---|
| BCX9930 | Phase II | No sales, data still needed |
| BCX9250 | Phase I | Very early, no proof yet |
| Galidesivir | Phase I | Broad antiviral idea, no traction |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.